SAS Output

18-JUN-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 0 0 0 0 0 BREAST
        9383 0 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 0 0 0 0 0  
      3 Endocrine Therapy Alone 2536 0 0 0 0 0  
        5083 0 0 0 0 0  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 19 14 12 9 6 1 SURV
      2 Randomization Non-surgical M 15 10 7 5 2 0  
      3 Patient Choice Surgery 65 20 11 8 3 0  
      4 Patient Choice Non-surgical M 100 0 0 0 0 0  
        199 44 30 22 11 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 696 196 82 18 4 1 CCD
      2 Site randomized: Control 559 227 113 62 21 3  
      3 SiteRand Int Risk: CSF 1060 470 296 169 54 17  
      4 SiteRand Int Risk: No CSF 814 372 191 94 33 7  
        3129 1265 682 343 112 28  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 579 337 190 102 33 10 BREAST
        579 337 190 102 33 10  
 
  2 Y 2 Observation 246 140 87 46 12 3  
      3 MK-3475 (Pembrolizumab) 242 140 81 42 14 2  
        488 280 168 88 26 5  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 119 105 57 29 10 2 SURV
        119 105 57 29 10 2  
 
  2 Y 1 Carvedilol 23 21 12 6 2 0  
      2 No prophylaxis 22 19 11 3 1 0  
      3 Observation 67 58 35 19 7 2  
        112 98 58 28 10 2  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 Y 1 Blinded Nutrition Drink 1 1 1 1 0 0 SXQOL
      2 Blinded Nutrition Drink 6 6 6 5 1 0  
        7 7 7 6 1 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 136 100 69 49 18 3 GU
      2 Tokyo-172 BCG 135 98 68 48 16 4  
      3 Prime + Tokyo-172 BCG 132 94 66 46 15 2  
        403 292 203 143 49 9  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 54 54 45 23 9 1 CCD
        54 54 45 23 9 1  
 
  2 Y 1 Control (Usual Care) 10 10 9 8 3 0  
      2 Intervention (STMDDM) 12 12 11 9 4 2  
        22 22 20 17 7 2  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y 1 Observation 7 7 7 7 6 2 SXQOL
        7 7 7 7 6 2  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 68 68 46 27 6 1 GU
        68 68 46 27 6 1  
 
  2 Y 1 Standard Systemic Therapy Only 16 16 12 9 1 0  
      2 SST + Surgery/RT 18 18 14 11 4 0  
        34 34 26 20 5 0  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 1 1 1 1 1 0 GU
        1 1 1 1 1 0  
 
  2 Y 1 Chemo + RT 1 1 1 1 1 0  
        1 1 1 1 1 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 573 80 62 38 20 16 PREV
        573 80 62 38 20 16  
 
  1 Y 1 Blinded drug 90 29 13 7 3 1  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 82 17 6 3 0 0  
        243 46 19 10 3 1  
 

18-JUN-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1614-HBV in Ca Pts, TAF vs SOC regtype: 1